CSL Reports Strong Financial Performance
Annual Profit Rises on Immunoglobulin Sales
Parent Company of CSL Behring Announces 20% Growth
CSL, Australia-based pharmaceuticals company, announced on Tuesday that its annual profit has increased by 20% on constant currency basis, reaching US$567 billion. The company's underlying profit (NPATA) for the 12 months ending June 30, 2023, was US$261 billion, a significant increase from the previous year.
CSL, the parent company of CSL Behring, attributed its success to the strong sales of its immunoglobulin products. Immunoglobulin sales reached US$567 billion, a 20% increase on a constant currency basis.
The company projected a 5-7% growth in fiscal 2025 revenue, largely in line with the consensus of 6.2%. CSL's profit surged to $264 billion, and the company projected further earnings growth of 10-13% for the next fiscal year.
This news highlights CSL's strong financial performance in recent months, driven by rising demand for its immunoglobulin products and the company's continued focus on innovation and growth.
Comments